drugset
drugset / Trial / NCT03587376

Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)

NCT03587376 ↗

Phase 0 Completed 9 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to determine T-cell mediated inflammatory immune response in some participants previously exposed to atabecestat.

Timeline

Start
2018-05-30
Primary completion
2018-08-23
Completion
2018-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Atabecestat Small molecule — —

Indications

Alzheimer disease